Numerous clinical trials have evaluated zidovudine across all development stages, from Early Phase 1 to Phase 4. These studies primarily address human immunodeficiency virus (HIV) infections, mother-to-child transmission, and HIV-2, while also investigating secondary conditions such as AIDS dementia complex, lipodystrophy, hepatitis B, and adult T-cell leukemia-lymphoma. Spanning completed, recruiting, active, and terminated protocols, these trials are supported by diverse sponsors, including government institutes, public health organizations, and pharmaceutical companies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01419561 | RECRUITING | KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8 |
National Cancer Institute (NCI) |
2011-09-08 | PHASE2 |
| NCT00092222 | ACTIVE_NOT_RECRUITING | Lymphoproliferative Disorder; HHV-8; Malignancy; HIV |
National Cancer Institute (NCI) |
2004-10-28 | PHASE2 |
| NCT02737046 | COMPLETED | Adult T-cell Leukemia-Lymphoma; ATLL |
University of Miami |
2016-12-12 | PHASE2 |
| NCT04731103 | COMPLETED | Aicardi-Goutières Syndrome |
University of Edinburgh |
2022-08-24 | PHASE2 |
| NCT00799864 | COMPLETED | HIV-1 |
Janssen Sciences Ireland UC |
2011-01 | PHASE2 |
| NCT03088410 | COMPLETED | HIV; Insulin Sensitivity; Diabetes Mellitus |
Ann & Robert H Lurie Children's Hospital of Chicago |
2016-08-22 | PHASE4 |
| NCT02712801 | COMPLETED | HIV/AIDS and Infections |
National Center for Women and Children's Health, China CDC |
2016-04 | PHASE4 |
| NCT02369406 | ACTIVE_NOT_RECRUITING | HIV; Pediatric AIDS |
Harvard School of Public Health (HSPH) |
2015-05-04 | PHASE2; PHASE3 |
| NCT03988452 | UNKNOWN | Human Immunodeficiency Virus |
Makerere University |
2019-07-30 | PHASE3 |
| NCT03394196 | TERMINATED | HIV-2 Infection |
University of Washington |
2018-07-04 | |
| NCT02431975 | COMPLETED | HIV |
Columbia University |
2015-08 | PHASE4 |
| NCT03991013 | Completed | HIV Infections |
University of Cape Town|Wellcome Trust|Médecins Sans Frontières Belgium |
2019-08-08 | Phase 2 |
| NCT02150993 | COMPLETED | HIV-2 Infection |
ANRS, Emerging Infectious Diseases |
2016-01-26 | PHASE2; PHASE3 |
| NCT00872872 | COMPLETED | NVP Plasma Level; NVP Related Mutation; 3TC Related Mutation |
Thai Red Cross AIDS Research Centre |
2008-05 | |
| NCT02655471 | COMPLETED | HTLV-I Infections; Tropical Spastic Paraparesis |
Universidad Peruana Cayetano Heredia |
2017-07-01 | EARLY_PHASE1 |
| NCT01618305 | COMPLETED | HIV Infections |
Westat |
2013-09-05 | PHASE4 |
| NCT01964755 | TERMINATED | Epstein Barr Virus Associated Non Hodgkin's Lymphoma; Epstein Barr Virus Associated Hodgkin's Lymphoma; Post-Transplant Lymphoproliferative Disease |
University of Miami |
2009-04-21 | PHASE2 |
| NCT01441063 | COMPLETED | Castleman Disease; Multicentric Castleman Disease; Giant Lymph Node Hyperplasia |
National Cancer Institute (NCI) |
2011-09-13 | PHASE2 |
| NCT01125696 | COMPLETED | HIV; Hepatitis B |
Centers for Disease Control and Prevention |
2012-05 | PHASE2 |
| NCT02832778 | UNKNOWN | HIV |
St Stephens Aids Trust |
2016-11-21 | PHASE1 |
| NCT02363452 | COMPLETED | Aicardi-Goutières Syndrome (AGS) |
Assistance Publique - Hôpitaux de Paris |
2015-09-10 | PHASE2 |
| NCT02499874 | COMPLETED | HIV |
St Stephens Aids Trust |
2015-08 | PHASE1 |
| NCT01818258 | COMPLETED | HIV Positive; Malnourished |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2015-10-26 | PHASE4 |
| NCT03642704 | Completed | Mother to Child HIV Transmission |
ANRS Emerging Infectious Diseases |
2017-02-22 | Phase 4 |
| NCT03178084 | COMPLETED | HIV/AIDS |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2014-10-15 | PHASE3 |
| NCT01061151 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2011-03-01 | PHASE3 |
| NCT01511237 | COMPLETED | HIV Infections |
Institut de Recherche pour le Developpement |
2011-12 | PHASE3 |
| NCT00074581 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | PHASE3 |
| NCT01352715 | COMPLETED | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2012-03-13 | PHASE3 |
| NCT01694017 | COMPLETED | HIV |
Tufts University |
2012-11 | PHASE4 |
| NCT01738555 | WITHDRAWN | Human Immunodeficiency Virus Infection |
RFS Pharma, LLC |
2013-04 | PHASE2 |
| NCT01340950 | COMPLETED | HIV Infections; Central Nervous System Diseases; Dementia |
University of California, San Diego |
2010-07 | PHASE4 |
| NCT01714414 | COMPLETED | HIV-1 Infection |
Michael Hoelscher |
2012-12 | PHASE2 |
| NCT01516970 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Janssen-Cilag G.m.b.H |
2011-11-25 | PHASE3 |
| NCT01565889 | COMPLETED | Hepatitis C; HIV |
Gilead Sciences |
2012-03 | PHASE1; PHASE2 |
| NCT00719602 | COMPLETED | HIV Infections; Malaria |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2009-08 | EARLY_PHASE1 |
| NCT00993031 | COMPLETED | Malaria; HIV Infections |
University of California, San Francisco |
2009-12-15 | PHASE3 |
| NCT01583439 | TERMINATED | HIV Infections |
Harvard School of Public Health (HSPH) |
2012-09 | |
| NCT01737359 | TERMINATED | Human Immunodeficiency Virus Infection |
RFS Pharma, LLC |
2012-12 | PHASE2 |
| NCT00936195 | WITHDRAWN | HIV Infection; Pregnancy; Breastfeeding; HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2010-01 | PHASE3 |
| NCT01540240 | UNKNOWN | HIV; Zidovudine Adverse Reaction |
University Hospital, Geneva |
2011-08 | PHASE2; PHASE3 |
| NCT01275625 | COMPLETED | HIV |
ViiV Healthcare |
2011-06 | PHASE4 |
| NCT00102960 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-07 | PHASE3 |
| NCT00608569 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2009-03 | |
| NCT01469520 | UNKNOWN | HIV; AIDS |
Elim Pediatric Pharmaceuticals Inc. |
2010-10 | PHASE1 |
| NCT01088516 | COMPLETED | HIV |
University of Zambia |
2008-12 | PHASE4 |
| NCT01772940 | COMPLETED | HIV-1 Infection |
Centre Hospitalier Universitaire Saint Pierre |
2008-12 | PHASE4 |
| NCT00234091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-04 | PHASE3 |
| NCT00424814 | COMPLETED | HIV Infections |
ANRS, Emerging Infectious Diseases |
2007-03 | PHASE2; PHASE3 |
| NCT00573001 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2008-07 | PHASE3 |
| NCT00854581 | TERMINATED | Lymphoma; Precancerous/Nonmalignant Condition |
University of Miami |
2007-11 | PHASE4 |
| NCT00335322 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Kirby Institute |
2007-02 | PHASE4 |
| NCT00099359 | COMPLETED | Disease Transmission, Vertical; Vertical Human Immunodeficiency Virus Transmission; HIV Infections |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2004-02 | PHASE3 |
| NCT00307151 | COMPLETED | HIV Infections |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2005-12 | PHASE2 |
| NCT00409591 | TERMINATED | HIV Infections; Pregnancy |
Institut de Recherche pour le Developpement |
2008-07 | PHASE3 |
| NCT00346567 | COMPLETED | HIV Infections |
Rigshospitalet, Denmark |
2006-06 | |
| NCT00915655 | COMPLETED | HIV-1 Infection |
Tibotec Pharmaceuticals, Ireland |
2009-07 | PHASE2 |
| NCT00084136 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-05 | PHASE4 |
| NCT00099632 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-03 | PHASE2 |
| NCT00001644 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1997-03-03 | PHASE1 |
| NCT00672412 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2008-10 | PHASE1; PHASE2 |
| NCT00164736 | COMPLETED | HIV Infections |
Centers for Disease Control and Prevention |
2004-03 | PHASE3 |
| NCT00470041 | COMPLETED | Healthy |
University Ghent |
2007-06 | PHASE1 |
| NCT00120510 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-07 | |
| NCT00405925 | COMPLETED | HIV Infections |
Rijnstate Hospital |
2003-03 | PHASE3 |
| NCT00834457 | COMPLETED | AIDS-related Kaposi's Sarcoma |
Parirenyatwa Hospital |
2007-06 | PHASE2; PHASE3 |
| NCT00100568 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-07 | |
| NCT00427297 | TERMINATED | HIV Infections |
University of Washington |
2007-09 | PHASE3 |
| NCT00528957 | COMPLETED | HIV Infections |
Gilead Sciences |
2006-12-28 | PHASE3 |
| NCT00270296 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-06 | PHASE2 |
| NCT00146380 | COMPLETED | HIV Infections |
Centers for Disease Control and Prevention |
2003-07 | PHASE2 |
| NCT00966160 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
University of Cologne |
1999-01 | PHASE3 |
| NCT00006441 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2003-02 | |
| NCT00109590 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-06 | PHASE2 |
| NCT01386970 | COMPLETED | HIV |
University of Colorado, Denver |
2005-05 | PHASE4 |
| NCT00342355 | COMPLETED | HIV |
National Institutes of Health Clinical Center (CC) |
2004-01 | PHASE4 |
| NCT00324649 | COMPLETED | HIV-1 |
Gilead Sciences |
2006-05 | PHASE4 |
| NCT00143689 | COMPLETED | HIV; Mitochondrial Toxicity |
University of British Columbia |
2002-04 | PHASE4 |
| NCT00084149 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-02 | PHASE2 |
| NCT00851630 | COMPLETED | HIV; Tuberculosis |
Duke University |
2004-06 | PHASE4 |
| NCT02229760 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2006-08 | PHASE1; PHASE2 |
| NCT00323544 | COMPLETED | HIV Infections |
Gilead Sciences |
2004-10 | PHASE3 |
| NCT00006617 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00100594 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-05 | |
| NCT00204308 | COMPLETED | HIV; Pregnancy |
University of North Carolina, Chapel Hill |
2005-03 | PHASE2 |
| NCT00098293 | COMPLETED | HIV-1 |
ViiV Healthcare |
2004-11 | PHASE3 |
| NCT00234923 | COMPLETED | HIV Infection |
Abbott |
2003-08 | PHASE3 |
| NCT00192595 | COMPLETED | HIV Infection; Hepatitis B Coinfection |
Kirby Institute |
2004-01 | PHASE4 |
| NCT00144183 | COMPLETED | Acquired Immunodeficiency Syndrome |
Boehringer Ingelheim |
2003-01 | PHASE3 |
| NCT00192621 | COMPLETED | HIV Infections; Dyslipidemias; Glucose Metabolism Disorders; Metabolic Diseases; Lipodystrophy; Cardiovascular Disease |
Kirby Institute |
2004-11 | PHASE4 |
| NCT00141284 | COMPLETED | HIV Infection; Hepatitis C |
Pfizer |
2005-10 | PHASE4 |
| NCT00041327 | COMPLETED | Lymphoma |
AIDS Malignancy Consortium |
2002-10 | PHASE2 |
| NCT00192660 | COMPLETED | HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease |
Kirby Institute |
2003-02 | PHASE4 |
| NCT00618176 | COMPLETED | HIV Infections |
Peking Union Medical College |
2005-01 | PHASE4 |
| NCT00144157 | COMPLETED | Acquired Immunodeficiency Syndrome |
Boehringer Ingelheim |
2003-06 | PHASE4 |
| NCT00142337 | COMPLETED | HIV Infections |
Institut de Recherche pour le Developpement |
2004-12 | PHASE2 |
| NCT00082394 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
GlaxoSmithKline |
2004-04-26 | PHASE4 |
| NCT00104429 | TERMINATED | Infection, Human Immunodeficiency Virus I; HIV Infection |
ViiV Healthcare |
2005-01 | PHASE2 |
| NCT00002524 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
1993-06 | PHASE2 |
| NCT00000897 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00059358 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-09 | PHASE1; PHASE2 |
| NCT00167674 | COMPLETED | HIV Infections |
University of Washington |
2003-11-03 | PHASE2 |
| NCT00779376 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2005-02 | |
| NCT00112047 | COMPLETED | HIV Infections |
Gilead Sciences |
2003-07 | PHASE3 |
| NCT00000993 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000587 | COMPLETED | Acquired Immunodeficiency Syndrome; Anemia; Hematologic Diseases; HIV Infections; Blood Disease |
Thomas Jefferson University |
1988-09 | PHASE2 |
| NCT00014937 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00273975 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2002-01 | PHASE2 |
| NCT00647946 | COMPLETED | Lipodystrophy |
Gilead Sciences |
2003-02 | PHASE2 |
| NCT00779233 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2004-09 | |
| NCT00038506 | COMPLETED | HIV Infection |
ViiV Healthcare |
2002-03 | PHASE4 |
| NCT00028327 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001119 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
1999-10 | |
| NCT00002571 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
1994-06 | PHASE2 |
| NCT00650637 | TERMINATED | Diarrhea |
Pfizer |
2003-01 | PHASE3 |
| NCT00601562 | COMPLETED | HIV Infections |
Roxane Laboratories |
2003-06 | |
| NCT00602550 | COMPLETED | HIV Infections |
Roxane Laboratories |
2003-06 | |
| NCT00043888 | COMPLETED | HIV Infections |
GlaxoSmithKline |
2002-01 | PHASE3 |
| NCT00000875 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00013897 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2001-02 | PHASE3 |
| NCT00006264 | COMPLETED | Lymphoma |
AIDS Malignancy Consortium |
2000-07 | PHASE2 |
| NCT00272480 | COMPLETED | HTLV-I-associated Myelopathy |
Imperial College London |
1999-11-08 | PHASE2; PHASE3 |
| NCT02249416 | COMPLETED | Healthy |
Boehringer Ingelheim |
2001-11 | PHASE1 |
| NCT00021463 | COMPLETED | HIV Infections; Lipodystrophy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002429 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1999-07 | PHASE3 |
| NCT00001066 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT02181933 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
1999-04 | PHASE3 |
| NCT02249130 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
1999-03 | PHASE2 |
| NCT00002411 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1998-03 | |
| NCT00000882 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002371 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1996-06 | PHASE3 |
| NCT00000982 | COMPLETED | Encephalopathies; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001111 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00001040 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00000679 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000965 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000662 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000672 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000979 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000678 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000671 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000961 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001008 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000716 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000659 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002020 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00002324 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
PHASE2 | |
| NCT00000971 | COMPLETED | Mycobacterium Avium-intracellulare Infection; HIV Infections |
Abbott |
PHASE1 | |
| NCT00002386 | COMPLETED | HIV Infections; Hemophilia A |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00002274 | COMPLETED | HIV Infections; Leukoencephalopathy, Progressive Multifocal |
Bristol-Myers Squibb |
||
| NCT00000841 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000878 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000765 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000918 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002401 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00000719 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00001045 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00122226 | UNKNOWN | HIV Infections; HIV-Associated Lipodystrophy Syndrome |
Amsterdam UMC, location VUmc |
2003-01 | PHASE4 |
| NCT00080522 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | |
| NCT00004998 | SUSPENDED | HIV Infections |
Agouron Pharmaceuticals |
1999-11 | PHASE2 |
| NCT00000687 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002190 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00001075 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002236 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00002369 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00000791 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002255 | COMPLETED | HIV Infections |
Amgen |
PHASE1 | |
| NCT00002110 | COMPLETED | HIV Infections |
Mylan Laboratories |
PHASE2 | |
| NCT00002217 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00002269 | COMPLETED | HIV Infections |
HEM Research |
||
| NCT00002290 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00004736 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000651 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000664 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000834 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002109 | COMPLETED | HIV Infections |
Immunobiology Research Institute |
PHASE3 | |
| NCT00002034 | COMPLETED | Cytomegalovirus Retinitis; HIV Infections |
Hoffmann-La Roche |
||
| NCT00001067 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00006396 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000851 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00217503 | COMPLETED | Lymphoma |
National Cancer Institute (NCI) |
2005-07 | PHASE2 |
| NCT00158405 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2002-12 | PHASE3 |
| NCT00000864 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002400 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00000862 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000823 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000738 | COMPLETED | AIDS Dementia Complex; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000754 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00398684 | COMPLETED | HIV Infections; Pregnancy |
Institut de Recherche pour le Developpement |
2001-01 | PHASE3 |
| NCT00001035 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001113 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002285 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000896 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002279 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
||
| NCT00000770 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000923 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000727 | COMPLETED | Pneumonia, Pneumocystis Carinii; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001095 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00086359 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | PHASE3 |
| NCT00000656 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000888 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000649 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
PHASE1 | |
| NCT00078247 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-10 | PHASE3 |
| NCT00000838 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002435 | COMPLETED | HIV Infections |
Pharmacia |
PHASE2 | |
| NCT00002035 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00002288 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000718 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00004585 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-10 | PHASE4 |
| NCT00000700 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000990 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002334 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00005002 | UNKNOWN | HIV Infections |
Agouron Pharmaceuticals |
PHASE3 | |
| NCT00001084 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00386230 | COMPLETED | HIV Infections; Pregnancy |
Institut de Recherche pour le Developpement |
1997-06 | PHASE3 |
| NCT00000711 | COMPLETED | HIV Infections; Cytopenias |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000661 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001997 | COMPLETED | HIV Infections |
Chiron Corporation |
||
| NCT00000902 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002168 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00002280 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00002013 | COMPLETED | HIV Infections |
Wyeth is now a wholly owned subsidiary of Pfizer |
||
| NCT00000978 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000709 | COMPLETED | AIDS Dementia Complex; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002391 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00002323 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
||
| NCT00002276 | COMPLETED | HIV Infections; Hemophilia A |
University of Pittsburgh |
||
| NCT00050895 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001354 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1993-03 | PHASE2 |
| NCT00000960 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000916 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000810 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002199 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00001011 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002263 | COMPLETED | HIV Infections; Cytopenias |
Sandoz |
||
| NCT00000647 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00389194 | COMPLETED | HIV Infections |
International Antiviral Therapy Evaluation Center |
2006-04 | PHASE4 |
| NCT00002322 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
PHASE2 | |
| NCT00001112 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00139178 | COMPLETED | HIV Associated Lipodystrophy Syndrome.; HIV; Hypercholesterolemia; Lipoatrophy |
Danish HIV Research Group |
2004-03 | PHASE4 |
| NCT00000919 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00004852 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-09 | PHASE2 |
| NCT00000652 | COMPLETED | HIV Infections |
National Cancer Institute (NCI) |
PHASE1 | |
| NCT00001063 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000693 | COMPLETED | Cytomegalovirus Retinitis; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002216 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000781 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002047 | COMPLETED | HIV Infections; Kidney Failure, Chronic |
Glaxo Wellcome |
||
| NCT00002044 | COMPLETED | AIDS Dementia Complex; Neuromuscular Diseases; HIV Infections |
Glaxo Wellcome |
||
| NCT00001993 | COMPLETED | HIV Infections |
G D Searle |
PHASE2 | |
| NCT00000728 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001002 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000751 | COMPLETED | HIV Infections; Pregnancy |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
PHASE3 | |
| NCT00087945 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | |
| NCT00000732 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000681 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002347 | COMPLETED | HIV Infections |
Parexel |
PHASE2 | |
| NCT00002443 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
||
| NCT00002312 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00004981 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00000865 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000742 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002270 | COMPLETED | HIV Infections; Leukoencephalopathy, Progressive Multifocal |
University of Miami |
||
| NCT00002033 | COMPLETED | HIV Infections |
Wyeth is now a wholly owned subsidiary of Pfizer |
||
| NCT00000994 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001010 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002286 | COMPLETED | HIV Infections; Psoriasis |
Glaxo Wellcome |
||
| NCT00002117 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00000973 | COMPLETED | Toxoplasmosis, Cerebral; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000695 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00005106 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-09 | PHASE4 |
| NCT00002409 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00002124 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
PHASE3 | |
| NCT00017719 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
2002-05 | PHASE3 |
| NCT00000999 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002410 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE3 | |
| NCT00000685 | WITHDRAWN | HIV Infections; Kidney Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000800 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002006 | COMPLETED | HIV Infections; Cytopenias |
Sandoz |
PHASE1 | |
| NCT00001087 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00004999 | SUSPENDED | HIV Infections |
Agouron Pharmaceuticals |
1999-08 | PHASE2 |
| NCT00002284 | COMPLETED | Lymphoma, Non-Hodgkin; HIV Infections |
Glaxo Wellcome |
||
| NCT00000723 | TERMINATED | Lymphoma, Non-Hodgkin; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002046 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000995 | COMPLETED | Cytomegalovirus Infections; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002256 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
||
| NCT00001057 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002063 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00256828 | COMPLETED | HIV Infections |
Clinical Trial Agency of HIV Study Group |
2004-06 | PHASE4 |
| NCT00001049 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002023 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00002333 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00000887 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002108 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00002155 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
||
| NCT00162643 | UNKNOWN | Acquired Immunodeficiency Syndrome |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2004-12 | PHASE4 |
| NCT00002079 | COMPLETED | HIV Infections |
G D Searle |
PHASE2 | |
| NCT00003261 | UNKNOWN | Lymphoma |
Centro di Riferimento Oncologico - Aviano |
1997-05 | PHASE2 |
| NCT00002183 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE1 | |
| NCT00000986 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00011895 | UNKNOWN | HIV Infections |
GlaxoSmithKline |
2001-02 | PHASE4 |
| NCT00000831 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001001 | COMPLETED | HIV Infections; Liver Diseases |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00013520 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00199979 | UNKNOWN | Hiv Infection With Antiretroviral Therapy Indication; CD4 Below 350/µL or Below 15% |
MEDEX |
2005-04 | PHASE3 |
| NCT00002203 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00270556 | COMPLETED | HIV |
Gilead Sciences |
2003-01 | PHASE2 |
| NCT00002379 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00001282 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1991-07 | PHASE2 |
| NCT00001048 | COMPLETED | HIV Infections; Leukoencephalopathy, Progressive Multifocal |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002378 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00000885 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00102206 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001036 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002281 | COMPLETED | HIV Infections; Cytopenias |
Amgen |
||
| NCT00002436 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00000637 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000734 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002001 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000983 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002326 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE1 | |
| NCT00002048 | COMPLETED | Lymphatic Disease; HIV Infections |
Glaxo Wellcome |
||
| NCT00000818 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000725 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000789 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002238 | COMPLETED | HIV Infections |
Bayer |
PHASE3 | |
| NCT00000991 | COMPLETED | Pneumonia, Pneumocystis Carinii; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002357 | COMPLETED | HIV Infections |
Hoechst Marion Roussel |
PHASE2 | |
| NCT00000736 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00000976 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000696 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001032 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001267 | COMPLETED | AIDS-Related Complex; Acquired Immunodeficiency Syndrome |
National Cancer Institute (NCI) |
1990-10 | PHASE3 |
| NCT00000706 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000944 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000987 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000743 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001104 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002096 | COMPLETED | Cytomegalovirus Infections; HIV Infections |
Hoffmann-La Roche |
PHASE1 | |
| NCT00002045 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00034086 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00005000 | UNKNOWN | HIV Infections |
Agouron Pharmaceuticals |
1999-12 | PHASE4 |
| NCT00127959 | COMPLETED | HIV Infections; Hepatitis B |
International Antiviral Therapy Evaluation Center |
2004-03 | PHASE4 |
| NCT00000680 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002007 | COMPLETED | HIV Infections; Cytopenias |
Sandoz |
||
| NCT00001022 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001007 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00014014 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000712 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001005 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002307 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00000657 | COMPLETED | AIDS Dementia Complex; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000629 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000701 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001094 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00043953 | COMPLETED | HIV Infections |
Abbott |
2002-08 | PHASE2 |
| NCT00002905 | UNKNOWN | Lymphoma |
Centro di Riferimento Oncologico - Aviano |
1995-06 | PHASE2 |
| NCT00001106 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000702 | COMPLETED | AIDS Dementia Complex; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002265 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00002081 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
||
| NCT00000628 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE1 | |
| NCT00002287 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00000855 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000952 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002184 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00002028 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00005764 | COMPLETED | HIV Infections; Lipodystrophy |
Glaxo Wellcome |
2000-05 | PHASE4 |
| NCT00000703 | COMPLETED | Lymphoma, Non-Hodgkin; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002162 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00000670 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000753 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000967 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002389 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00000760 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001989 | COMPLETED | HIV Infections |
Genelabs Technologies |
PHASE2 | |
| NCT00002320 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00000705 | COMPLETED | HIV Infections; Hemophilia A |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002376 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00002416 | COMPLETED | HIV Infections |
Triangle Pharmaceuticals |
PHASE3 | |
| NCT00432016 | COMPLETED | HIV Infections |
RFS Pharma, LLC |
2007-02 | PHASE1; PHASE2 |
| NCT00002367 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00000625 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000682 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001085 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000989 | COMPLETED | Cytomegalovirus Retinitis; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00197613 | COMPLETED | AIDS; HIV Infection |
Harvard School of Public Health (HSPH) |
2002-12 | PHASE3 |
| NCT00000750 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001025 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000891 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00199121 | UNKNOWN | HIV |
Johann Wolfgang Goethe University Hospital |
PHASE4 | |
| NCT00000920 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000755 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000731 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000963 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000969 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000872 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000870 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000803 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001003 | COMPLETED | Pneumonia, Pneumocystis Carinii; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002208 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE3 | |
| NCT00000720 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00001029 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002086 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE2 | |
| NCT00075231 | COMPLETED | HIV Infections |
Abbott |
2003-12 | PHASE2 |
| NCT00001083 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000903 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002195 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00031070 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000814 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001024 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002014 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE1 | |
| NCT00002179 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00000694 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-25)
Check the
Zidovudine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.